Key facts
- Metaphore’s last known valuation is $219.0M (Apr 2026).
- It has raised $117.0M; the latest was Later Stage VC ($85.0M) in Apr 2026.
- Notable investors include Global Brain, Flagship Pioneering.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Metaphore
- ·The full record, as it builds
Funding rounds
No funding rounds for Metaphore are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metaphore
Operator of a biotechnology company intended to trigger a desired biological response through biomimicry. The company's platform helps to generate insights to design new molecules tuned for therapeutic benefits, enabling drug discovery companies to get the desired outcomes.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 47
- Website
- metaphorebio.com/
- Ownership
- Privately Held (backing)
Metaphore doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metaphore shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metaphore in its N-PORT filings yet. We sweep new filings monthly.